Eluxadoline

• Irritable Bowel Syndrome with Diarrhea (IBS-D)
• IBS-D Abdominal Pain
• Chronic Diarrhea from IBS
• Functional GI Disorders

Eluxadoline is a mixed opioid receptor modulator approved for adults with irritable bowel syndrome with diarrhea, often abbreviated IBS-D. The drug acts almost entirely within the gastrointestinal tract, slowing intestinal motility and dampening visceral pain signaling without producing the euphoria, sedation, or respiratory depression associated with systemic opioids. Because of its targeted action and low systemic absorption, eluxadoline is a useful option for patients whose abdominal pain and loose stools persist despite dietary modification, soluble fiber, antispasmodics, and conventional antidiarrheals such as loperamide. It is part of a broader gastrointestinal treatment arsenal that increasingly tailors therapy to specific IBS subtypes.

Mechanism of Action

Eluxadoline has an unusual triple-action profile at the three classical opioid receptor types. It is a mu-opioid receptor agonist, a delta-opioid receptor antagonist, and a kappa-opioid receptor agonist. In the enteric nervous system, mu-receptor activation slows propulsive contractions, prolongs intestinal transit time, and reduces water secretion into the bowel lumen — the same mechanism that makes loperamide effective, but achieved through a molecule that engages multiple receptor types simultaneously. The kappa-receptor agonism is thought to contribute meaningfully to visceral analgesia, addressing the abdominal pain component of IBS-D that pure motility-slowing agents do not always relieve.

The delta-receptor antagonism is a clever design feature. Pure mu-agonists tend to cause bothersome constipation and may produce tolerance over time; delta antagonism appears to mitigate the constipating effect while potentially enhancing analgesia. Eluxadoline undergoes extensive first-pass metabolism and is a substrate of P-glycoprotein efflux, so very little intact drug reaches the central nervous system. Plasma levels are low and CNS opioid effects are minimal — patients do not become drowsy, euphoric, or respiratory-depressed at therapeutic doses. Despite this favorable safety profile in most patients, the drug retains enough affinity for opioid receptors at the sphincter of Oddi to provoke spasm in vulnerable individuals, which underlies its most important contraindications. Because of the opioid receptor activity, eluxadoline is a Schedule IV controlled substance, though its abuse potential is considered low.

Clinical Use

Eluxadoline is FDA-approved for the treatment of IBS-D in adults. The American College of Gastroenterology and American Gastroenterological Association IBS guidelines position it as a second- or third-line agent after first-line measures: dietary modification (often a low-FODMAP trial), soluble fiber, antispasmodics, and over-the-counter loperamide. Patients best suited for eluxadoline have predominant diarrhea with significant abdominal pain, an intact gallbladder, no history of pancreatitis or biliary disease, and minimal alcohol use. Pivotal trials demonstrated improvement in both stool consistency and abdominal pain compared with placebo, with composite responder rates around 25 to 30 percent at 26 weeks — modest but meaningful in a condition known for treatment refractoriness.

Alternatives include rifaximin, a non-absorbed antibiotic with a 2-week course providing several months of relief, and tegaserod (in selected populations). Bile acid sequestrants such as colesevelam help when bile acid malabsorption contributes. Tricyclic antidepressants at low doses can address visceral pain. Choice among these depends on symptom dominance, comorbidities, and prior response. Patient selection for eluxadoline matters more than for almost any other IBS drug because the contraindication list is long: no gallbladder, suspected biliary obstruction, sphincter of Oddi disease, alcoholism or more than three drinks daily, history of pancreatitis or structural pancreatic disease, severe hepatic impairment, or severe constipation. Skipping that screening risks serious harm. The MedlinePlus monograph at medlineplus.gov outlines patient-facing details.

How to Take It

The usual dose is one 100 mg tablet twice daily, taken with food in the morning and evening. A reduced dose of 75 mg twice daily applies to patients without a gallbladder, those receiving certain OATP1B1 inhibitors such as cyclosporine or gemfibrozil, those with mild to moderate hepatic impairment, or anyone who does not tolerate the full 100 mg dose. Taking the medication with food is not optional — empty-stomach administration meaningfully raises the risk of sphincter of Oddi spasm.

If a dose is missed, take the next scheduled dose at the usual time; do not double up to make up for a missed tablet. Store at room temperature in the original container away from moisture. During the first week of therapy, mild constipation, transient nausea, or abdominal discomfort are common and usually fade. Severe abdominal pain — particularly upper abdominal or right upper quadrant pain that radiates to the back or shoulder, with or without nausea and vomiting — is a red flag that should prompt immediate discontinuation and medical evaluation. Patients should also keep loperamide and other constipating agents to a minimum during therapy because additive effects can produce serious constipation, occasionally requiring hospitalization. Resources from the American Gastroenterological Association provide additional context on IBS-D management.

Monitoring and Follow-Up

Before starting eluxadoline, clinicians should confirm a clear diagnosis of IBS-D using Rome IV criteria and rule out alarm features such as weight loss, bleeding, anemia, nocturnal symptoms, or family history of inflammatory bowel disease or colorectal cancer. A baseline assessment includes liver function tests, an alcohol use review, and confirmation of gallbladder presence — patients who have undergone cholecystectomy face roughly a fourfold higher risk of pancreatitis on eluxadoline, so the lower 75 mg dose is mandatory and risk discussion is essential.

No routine laboratory monitoring is required for ongoing therapy. The most important monitoring is symptom-based: documenting abdominal pain scores, stool frequency and consistency (Bristol stool scale), and quality-of-life measures at follow-up visits 4 to 12 weeks after initiation and periodically thereafter. Patients who fail to achieve meaningful response within 8 to 12 weeks should generally discontinue. Watch for signs of pancreatitis (lipase elevation above three times the upper limit of normal, severe epigastric pain) or biliary spasm. New constipation severe enough to interfere with daily life should trigger dose reduction or discontinuation.

Special Populations

Elderly patients have not shown overall differences in safety or efficacy in clinical trials, but the higher background prevalence of cholecystectomy and biliary disease in this group warrants extra caution and lower starting doses. Patients with mild or moderate hepatic impairment should use 75 mg twice daily; severe impairment (Child-Pugh C) is a contraindication. No dose adjustment is required for renal impairment, though data in severe renal disease are limited. Pregnancy data are sparse — animal studies did not show teratogenicity, but human exposure is minimal; use during pregnancy is recommended only when benefits clearly outweigh risks. Eluxadoline is poorly absorbed, so breastfeeding is likely compatible, though caution is reasonable. Safety and efficacy have not been established in patients under 18, and the drug is not used in pediatrics.

When to Contact Your Doctor

Seek emergency care immediately for severe abdominal pain, especially in the upper abdomen, that radiates to the back or shoulder, with or without nausea, vomiting, or fever — these features may indicate sphincter of Oddi spasm or pancreatitis, both of which can become life-threatening. Yellowing of the skin or eyes, dark urine, or pale stools may signal biliary obstruction or hepatotoxicity. Severe constipation that does not respond to fluid intake, fiber, or simple laxative measures within several days requires medical attention. New chest pain, fainting, or signs of an allergic reaction such as hives, facial swelling, or difficulty breathing warrant emergency evaluation. Any worsening of baseline IBS symptoms or development of new alarm features such as bloody stools, unintended weight loss, or fevers should be reported promptly so a fresh diagnostic workup can be considered.

Patients on concurrent statin therapy should be alert to muscle pain or weakness, particularly with rosuvastatin, because eluxadoline can raise rosuvastatin levels. New constipation accompanied by abdominal distension, inability to pass gas, or vomiting may signal more serious bowel dysfunction and warrants prompt evaluation. Patients who develop concerning symptoms should not simply take additional antidiarrheal medication, since combining drugs that slow gut motility can produce dangerous constipation. The National Institute of Diabetes and Digestive and Kidney Diseases provides additional patient education at niddk.nih.gov.

If eluxadoline might be appropriate for your symptoms, or if you are already taking it and need follow-up assessment, contact us or schedule a visit with the Zimmer Medical Group team to discuss next steps.